The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Shi, Li ^a   Chen, Shaohua ^a   Yang, Lijian ^a   Li, Yangqiu ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B LYMPHOCYTE; BIOLOGICAL FUNCTIONS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER STAGING; CELL POPULATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEEDBACK SYSTEM; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGLOBULIN GENE; LARGE CELL LYMPHOMA; LEUKEMIA CELL; LUNG SMALL CELL CANCER; LYMPHOMA CELL; MULTIPLE MYELOMA; NATURAL KILLER T CELL; NONHODGKIN LYMPHOMA; PRE B LYMPHOCYTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; STEM CELL TRANSPLANTATION; SUBTRACTIVE HYBRIDIZATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD274; CELL DIFFERENTIATION; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNE TOLERANCE; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 84884698526     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-74     Document Type: Review

References (53)

1. Cellular immunotherapy for refractory hematological malignancies. Reagan JL, Fast LD, Safran H, Nevola M, Winer ES, Castillo JJ, Butera JN, Quesenberry MI, Young CT, Quesenberry PJ, J Transl Med 2013 11 150 10.1186/1479-5876-11-150 23782682
2. Therapeutic advancement of chronic lymphocytic leukemia. Lu K, Wang X, J Hematol Oncol 2012 5 55 10.1186/1756-8722-5-55 22980425
3. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. Takahashi S, J Hematol Oncol 2011 4 13 10.1186/1756-8722-4-13 21453545
4. Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Chen X, Woiciechowsky A, Raffegerst S, Schendel D, Kolb HJ, Roskrow M, Br J Haematol 2000 111 3 817 825 11122143
5. Alternative expression of TCRzeta related genes in patients with chronic myeloid leukemia. Zha X, Yan X, Shen Q, Zhang Y, Wu X, Chen S, Li B, Yang L, Geng S, Weng J, et al. J Hematol Oncol 2012 5 74 10.1186/1756-8722-5-74 23228155
6. Restricted TRBV repertoire in CD4+ and CD8+ T-cell subsets from CML patients. Li Y, Geng S, Du X, Chen S, Yang L, Wu X, Li B, Schmidt CA, Przybylski GK, Hematology 2011 16 1 43 49 10.1179/102453311X12902908411634 21269567
7. Decreased level of recent thymic emigrants in CD4+ and CD8+T cells from CML patients. Li Y, Geng S, Yin Q, Chen S, Yang L, Wu X, Li B, Du X, Schmidt CA, Przybylski GK, J Transl Med 2010 8 47 10.1186/1479-5876-8-47 20470401
8. Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Rezvany MR, Jeddi-Tehrani M, Osterborg A, Kimby E, Wigzell H, Mellstedt H, Blood 1999 94 3 1063 1069 10419899
9. Defective expression of the T-cell receptor-CD3 zeta chain in T-cell acute lymphoblastic leukaemia. Torelli GF, Paolini R, Tatarelli C, Soriani A, Vitale A, Guarini A, Santoni A, Foa R, Br J Haematol 2003 120 2 201 208 10.1046/j.1365-2141.2003.04044.x 12542476
10. A cell culture model for T lymphocyte clonal anergy. Schwartz RH, Science 1990 248 4961 1349 1356 10.1126/science.2113314 2113314
11. Functional differences between low- and high-affinity CD8(+) T cells in the tumor environment. Bos R, Marquardt KL, Cheung J, Sherman LA, Oncoimmunology 2012 1 8 1239 1247 10.4161/onci.21285 23243587
12. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. Norde WJ, Maas F, Hobo W, Korman A, Quigley M, Kester MG, Hebeda K, Falkenburg JH, Schaap N, de Witte TM, et al. Cancer Res 2011 71 15 5111 5122 10.1158/0008-5472.CAN-11-0108 21659460
13. Activation-induced expression of human programmed death-1 gene in T-lymphocytes. Vibhakar R, Juan G, Traganos F, Darzynkiewicz Z, Finger LR, Exp Cell Res 1997 232 1 25 28 10.1006/excr.1997.3493 9141617
14. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Ishida Y, Agata Y, Shibahara K, Honjo T, EMBO J 1992 11 11 3887 3895 1396582
15. IMGT Colliers de Perles and IgSF domain standardization for T cell costimulatory activatory (CD28, ICOS) and inhibitory (CTLA4, PDCD1 and BTLA) receptors. Garapati VP, Lefranc MP, Dev Comp Immunol 2007 31 10 1050 1072 10.1016/j.dci.2007.01.008 17391759
16. The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. Finger LR, Pu J, Wasserman R, Vibhakar R, Louie E, Hardy RR, Burrows PD, Billips LG, Gene 1997 197 1-2 177 187 9332365
17. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Shinohara T, Taniwaki M, Ishida Y, Kawaichi M, Honjo T, Genomics 1994 23 3 704 706 10.1006/geno.1994.1562 7851902
18. PD-1/PD-L pathway and autoimmunity. Okazaki T, Wang J, Autoimmunity 2005 38 5 353 357 10.1080/08916930500124072 16227150
19. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Dong H, Zhu G, Tamada K, Chen L, Nat Med 1999 5 12 1365 1369 10.1038/70932 10581077
20. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ, Immunity 2007 27 1 111 122 10.1016/j.immuni.2007.05. 016 17629517
21. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH, J Exp Med 2009 206 13 3015 3029 10.1084/jem.20090847 20008522
22. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Chen L, Nat Rev Immunol 2004 4 5 336 347 10.1038/nri1349 15122199
23. PD-1 and PD-1 ligands: from discovery to clinical application. Okazaki T, Honjo T, Int Immunol 2007 19 7 813 824 10.1093/intimm/dxm057 17606980
24. PD-1 and its ligands in tolerance and immunity. Keir ME, Butte MJ, Freeman GJ, Sharpe AH, Annu Rev Immunol 2008 26 677 704 10.1146/annurev.immunol. 26.021607.090331 18173375
25. Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. Freeman GJ, Proc Natl Acad Sci USA 2008 105 30 10275 10276 10.1073/pnas. 0805459105 18650389
26. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL, J Immunol 2004 173 2 945 954 15240681
27. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Nishimura H, Agata Y, Kawasaki A, Sato M, Imamura S, Minato N, Yagita H, Nakano T, Honjo T, Int Immunol 1996 8 5 773 780 10.1093/intimm/8.5.773 8671666
28. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Ishida M, Iwai Y, Tanaka Y, Okazaki T, Freeman GJ, Minato N, Honjo T, Immunol Lett 2002 84 1 57 62 10.1016/S0165-2478(02)00142-6 12161284
29. Expression of programmed death 1 ligands by murine T cells and APC. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, et al. J Immunol 2002 169 10 5538 5545 12421930
30. Association between single nucleotide polymorphism of PD-L1 gene and non-small cell lung cancer susceptibility in a Chinese population. Chen YB, Mu CY, Chen C, Huang JA, Asia Pac J Clin Oncol 2012 Doi:10.111/ajco.12307
31. PD-1 inhibits antiviral immunity at the effector phase in the liver. Iwai Y, Terawaki S, Ikegawa M, Okazaki T, Honjo T, J Exp Med 2003 198 1 39 50 10.1084/jem.20022235 12847136
32. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, Yamazaki T, Azuma M, Iwai H, Khoury SJ, et al. J Exp Med 2003 198 1 63 69 10.1084/jem.20022125 12847137
33. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, Sharpe AH, Eur J Immunol 2003 33 10 2706 2716 10.1002/eji.200324228 14515254
34. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. Wiendl H, Mitsdoerffer M, Schneider D, Chen L, Lochmuller H, Melms A, Weller M, FASEB J 2003 17 13 1892 1894 12923066
35. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. Salama AD, Chitnis T, Imitola J, Ansari MJ, Akiba H, Tushima F, Azuma M, Yagita H, Sayegh MH, Khoury SJ, J Exp Med 2003 198 1 71 78 10.1084/jem.20022119 12847138
36. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Nat Med 2002 8 8 793 800 12091876
37. Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. Chen X, Liu S, Wang L, Zhang W, Ji Y, Ma X, Cancer Biol Ther 2008 7 5 622 627 10.4161/cbt.7.5.5689 18756622
38. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF, Blood 2009 114 8 1528 1536 10.1182/blood-2008-09-179697 19420358
39. Tumor immunotherapy directed at PD-1. Ribas A, N Engl J Med 2012 366 26 2517 2519 10.1056/NEJMe1205943 22658126
40. Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant. Matte-Martone C, Venkatesan S, Tan HS, Athanasiadis I, Chang J, Pavisic J, Shlomchik WD, J Immunol 2011 187 4 1653 1663 10.4049/jimmunol.1100311 21768400
41. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Brusa D, Serra S, Coscia M, Rossi D, D'Arena G, Laurenti L, Jaksic O, Fedele G, Inghirami G, Gaidano G, et al. Haematologica 2013 98 6 953 963 10.3324/haematol.2012.077537 23300177
42. Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma. Shimauchi T, Kabashima K, Nakashima D, Sugita K, Yamada Y, Hino R, Tokura Y, Int J Cancer 2007 121 12 2585 2590 10.1002/ijc.23042 17721918
43. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y, Akimoto M, Suzuki S, Matsushita K, Uozumi K, et al. Leukemia 2009 23 2 375 382 10.1038/leu.2008.272 18830259
44. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tashima M, Kondo T, Ohmori K, Kurata M, Hayashi T, et al. Blood 2008 111 6 3220 3224 10.1182/blood-2007-05-085159 18203952
45. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ, Azuma M, Anderson AC, Kuchroo VK, et al. Blood 2011 117 17 4501 4510 10.1182/blood-2010-10-310425 21385853
46. PD-L1/PD-1 Co-stimulation, a brake for T cell activation and a T cell differentiation signal. Liechtenstein T, Dufait I, Bricogne C, Lanna A, Pen J, Breckpot K, Escors D, J Clin Cell Immunol 2012 12
47. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. Christiansson L, Soderlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B, Olsson-Stromberg U, Loskog AS, PLoS One 2013 8 1 55818 10.1371/journal.pone.0055818 23383287
48. Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer. Peng W, Lizee G, Hwu P, Oncoimmunology 2013 2 2 22691 10.4161/onci.22691 23524510
49. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. N Engl J Med 2012 366 26 2455 2465 10.1056/NEJMoa1200694 22658128
50. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, et al. Clin Cancer Res 2013 19 13 3462 3473 10.1158/1078-0432.CCR-13-0855 23674495
51. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM, Clin Cancer Res 2011 17 13 4232 4244 10.1158/1078-0432.CCR-10-2660 21540239
52. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A, Nagler A, Clin Cancer Res 2008 14 10 3044 3051 10.1158/1078-0432.CCR-07-4079 18483370
53. Changes in the MALT1-A20-NF-kappaB expression pattern may be related to T cell dysfunction in AML. Shi L, Chen S, Lu Y, Wang X, Xu L, Zhang F, Yang L, Wu X, Li B, Li Y, Cancer Cell Int 2013 13 1 37 10.1186/1475-2867-13-37 23627638